Cat. No. 4536
Alternative Name: R 848
Chemical Name: 1-[4-Amino-2-(ethoxymethyl)-1H-imid
Biological ActivityToll-like receptor 7 (TLR7) agonist. Induces upregulation of IL-6, IL-12, IFN-γ and iNOS expression in mouse bone marrow-derived macrophages (BMMs). Inhibits RANKL-induced osteoclast differentiation in mouse BMMs and human peripheral blood monocytes. Also promotes the differentiation of MDSCs into macrophages and dendritic cells. Proinflammatory and antiviral.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Lee et al (2014) Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells. Arch.Pharm.Res. 37 1234. PMID: 24748512.
Miyamoto et al (2012) R848, a toll-like receptor 7 agonist, inhibits osteoclast differentiation but not survival or bone-resorbing function of mature osteoclasts. Cytotechnology. 64 331. PMID: 22358541.
Dockrell and Kinghorn (2001) Imiquimod and resiquimod as novel immunomodulators. J.Antimicrob.Chemother. 48 751. PMID: 11733457.
Wagner et al (1999) Modulation of TH1 and Th2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol. 191 10. PMID: 9918682.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Resiquimod from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Resiquimod, supplier, proinflammatory, toll, like, receptors, ligands, agonists, TLR7, cytokines, interferons, interleukins, R848, R_848, myeloid-derived, suppressor, cells, MDSCs, tumor, microenvironment, Tocris Bioscience, Toll-like Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Potent and selective inhibitor of integrins αvβ3 and αvβ5SM 324405
Potent TLR7 agonistRS 09
TLR4 peptide agonist; acts as an adjuvant in vivo
October 30 - November 3, 2016
Boston, MA, USA